Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DynPort Vaccine Co.
Phase I smallpox vaccine clinical trial completed
May 14th, 2003
Computer Sciences Corporation (CSC) announced that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International, a vaccine development company focused on biodefense vaccines, has completed phase I testing of the safety and immunogenicity of an improved cell-cultured smallpox vaccine (CCSV). In this trial, 100% of 350 volunteers exhibited a positive response to either the CCSV or the historic calf lymph-produced smallpox vaccine (Dryvax). However, the incidence of vaccine-related fatigue, application site rash, increased temperature, headache, lymphangitis and nausea was at least 8% less common for volunteers receiving CCSV than Dryvax. ...
Source: Biotech Week (2003-05-14)
|
